Mother Discovers Son's Autism Diagnosis Masked Rare Genetic Disorder Sanfilippo Syndrome
A mother shares her experience discovering her 10-year-old son Merrick, initially diagnosed with autism and ADHD, actually has Sanfilippo syndrome, a rare progressive genetic disorder often called childhood dementia. The family pursued multiple therapies for years before a test result revealed the underlying condition, which causes gradual loss of speech, mobility, and independence. The case highlights how rare genetic disorders can be misdiagnosed or overlooked when symptoms overlap with more common neurodevelopmental conditions.
A Newsweek first-person account describes a mother's journey discovering her son's true diagnosis after years of confusion. Merrick displayed characteristics consistent with autism—advanced knowledge in specific areas, speech delays, sensory sensitivities, and social communication challenges—leading to an autism and ADHD diagnosis around age four and a half. However, around age five, the child began experiencing regression in previously acquired skills including language, fine motor control, and focus, which the family initially attributed to pandemic-related disruption. After years of additional therapies and specialist appointments, genetic testing in June 2024 revealed Merrick has Sanfilippo syndrome, a progressive rare genetic disorder characterized by gradual loss of cognitive and physical abilities. The mother reflects on the emotional weight of the delayed diagnosis, the missed opportunity for clinical trials due to his age at diagnosis, and her ongoing commitment to maintaining connection with her son while managing his complex medical and developmental needs.
What's missing
The article does not provide information about: the prevalence or typical age of Sanfilippo syndrome diagnosis; whether there are established screening protocols that might have identified this condition earlier; the specific genetic mutations involved; current treatment options beyond supportive care; or prognosis and life expectancy data for individuals with this condition. Additionally, no expert medical commentary or perspective from geneticists or neurologists is included to contextualize the diagnostic challenges or the relationship between autism and Sanfilippo syndrome presentations.
What different sources said
- NewsweekCenter
I Thought My Son Had Autism—the Truth Was So Much Worse
Related
Multi-Cancer Blood Test Galleri Fails Primary Trial Endpoint
A major clinical trial of Galleri, a blood test designed to detect multiple cancers early, failed to meet its primary goal of reducing late-stage cancer diagnoses when results were announced in February. Multi-cancer early detection (MCED) tests aim to improve survival rates by identifying disease at earlier, more treatable stages. The failure raises questions about the effectiveness of this promising diagnostic approach despite initial scientific enthusiasm.
Study Uses CPAP Data to Measure Social Jet Lag in Sleep Apnea Patients
Researchers analyzed CPAP adherence records from nearly 3,000 obstructive sleep apnea patients to measure social jet lag—the circadian misalignment between work and free days. About 16-21% of patients showed moderate to severe social jet lag, with prevalence highest in younger and middle-aged adults and declining after age 65. The findings suggest CPAP devices could routinely screen for circadian misalignment, potentially identifying patients who need additional behavioral or activity-based interventions.
FDA Updates Alli Label to Warn of Rare but Potentially Fatal Kidney Problems
The FDA has approved updated labeling for Alli, an over-the-counter weight loss pill, to warn of rare risks including acute kidney injury, kidney stones, and oxalate nephropathy. The agency now instructs people with kidney disease history to consult a doctor before use and directs all users to stop taking the drug if they experience symptoms like back pain, blood in urine, or leg swelling. This warning is significant because Alli is the only OTC weight loss medication available in the U.S., and approximately 40 million people have used orlistat (Alli's generic form) since its approval in 1999.